About Janux Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.januxrx.com/
Frequently Asked Questions
What is the 52-week range for JANX?
The 52-week high is $35.34 and the 52-week low is $12.12.
What is the P/E ratio for JANX?
The P/E ratio data is currently unavailable.
What is the dividend yield for JANX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -10.79%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -294.36%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.02.
Analyst Recommendation Trends
Wall Street analyst consensus for JANX over the last few months:
Latest JANX News
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?
Iovance Biotherapeutics (IOVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is Janux’s Dual JANX013–JANX007 Trial Advancing a Durable Precision Oncology Platform for JANX?
Janux Therapeutics has recently dosed the first patient in its Phase 1 trial evaluating JANX013 in combination with JANX007 for metastatic castration-resistant prostate cancer, marking a new step in its clinical pipeline. This trial brings fresh attention to Janux Therapeutics’ prostate cancer platform, highlighting how the company is expanding its precision oncology approach into a difficult-to-treat setting. We’ll now examine how progress in this metastatic castration-resistant prostate...
Janux Therapeutics (JANX) Advances Prostate Cancer Trial While Valuation Still Looks Pricey
Janux Therapeutics (JANX) just hit a clinical milestone, dosing the first patient in its Phase 1 trial of JANX013 with JANX007 for metastatic castration-resistant prostate cancer. This development is sharpening investor focus on this prostate cancer platform. The JANX share price has cooled in the near term, with a 1-month share price return down 9.6% and a 7-day move down 1.75%, even as the 90-day share price return is up 6.36% and the year-to-date share price return stands at 19.41%. Over a...
Janux Therapeutics, Inc. (JANX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow
2026-09-17. The following slide deck was published by Janux Therapeutics, Inc.
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
Prostate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
SAN DIEGO, September 14, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer (mCRPC).
Janux Therapeutics Doses First Patient In The Phase 1 Clinical Trial For JANX013, Its PSMA-Targeted Tumor-Activated CD28 Co-Stimulatory Bispecific, In Patients With Metastatic Castration-Resistant Prostate Cancer
The program is initially being developed in combination with JANX007, with the goal of further enhancing the durability of anti-tumor immune responses through tumor-restricted CD28 co-stimulation. Over time, Janux
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-31 | Campbell David Alan | -123,840 | - | - |
| 2026-07-08 | Campbell David Alan | -7,000 | - | - |
| 2026-07-08 | Campbell David Alan | +7,000 | $4.21 | $29,470 |
| 2026-06-11 | Simson Jake | +15,500 | - | - |
| 2026-06-11 | Simson Jake | +5,500 | - | - |
| 2026-06-11 | Hernday Natasha | +15,500 | - | - |
| 2026-06-11 | Hernday Natasha | +5,500 | - | - |
| 2026-06-11 | Kung Winston | +15,500 | - | - |
| 2026-06-11 | Kung Winston | +5,500 | - | - |
| 2026-06-11 | Barrett Ronald W | +15,500 | - | - |
| 2026-06-11 | Barrett Ronald W | +5,500 | - | - |
| 2026-06-11 | RA Capital Healthcare Fund LP | +15,500 | - | - |
| 2026-06-11 | RA Capital Healthcare Fund LP | +5,500 | - | - |
| 2026-06-11 | CAPPS VICKIE L | +15,500 | - | - |
| 2026-06-11 | CAPPS VICKIE L | +5,500 | - | - |
| 2026-06-11 | DOBMEIER ERIC | +15,500 | - | - |
| 2026-06-11 | DOBMEIER ERIC | +5,500 | - | - |
| 2026-06-02 | Doyle Janeen Noel | -4,059 | $14.029 | $56,944 |
| 2026-05-11 | Dobek Maria | -2,038 | $14.17 | $28,878 |
| 2026-02-02 | Go William | +154,000 | - | - |
| 2026-02-02 | Go William | +44,000 | - | - |
| 2026-01-02 | Doyle Janeen Noel | +126,000 | - | - |
| 2026-01-02 | Doyle Janeen Noel | +36,000 | - | - |
| 2026-01-02 | McIver Zachariah | +101,500 | - | - |
| 2026-01-02 | McIver Zachariah | +29,000 | - | - |
| 2026-01-02 | McIver Zachariah | -2,714 | $13.73 | $37,263 |
| 2026-01-02 | Dobek Maria | +42,600 | - | - |
| 2026-01-02 | Dobek Maria | +18,935 | - | - |
| 2026-01-02 | Dobek Maria | -1,462 | $13.73 | $20,073 |
| 2026-01-02 | DiRaimondo Thomas | +109,900 | - | - |
| 2026-01-02 | DiRaimondo Thomas | +31,400 | - | - |
| 2026-01-02 | DiRaimondo Thomas | -2,505 | $13.73 | $34,394 |
| 2026-01-02 | Winter Charles M. | +100,100 | - | - |
| 2026-01-02 | Winter Charles M. | +28,600 | - | - |
| 2026-01-02 | Winter Charles M. | -2,401 | $13.73 | $32,966 |
| 2026-01-02 | Meyer Andrew Hollman | -1,879 | $13.73 | $25,799 |
| 2026-01-02 | Campbell David Alan | +338,100 | - | - |
| 2026-01-02 | Campbell David Alan | +96,600 | - | - |
| 2026-01-02 | Campbell David Alan | -8,072 | $13.73 | $110,829 |
| 2025-12-01 | Meyer Andrew Hollman | -3,333 | - | - |
| 2025-12-01 | Meyer Andrew Hollman | -633 | $33.5247 | $21,221 |
| 2025-12-01 | Meyer Andrew Hollman | -2,700 | $32.8548 | $88,708 |
| 2025-12-01 | Meyer Andrew Hollman | +3,333 | $10.59 | $35,296 |
| 2025-11-14 | Meyer Andrew Hollman | -3,333 | - | - |
| 2025-11-14 | Meyer Andrew Hollman | -3,333 | $30 | $99,990 |
| 2025-11-14 | Meyer Andrew Hollman | +3,333 | $10.59 | $35,296 |
| 2025-10-28 | Meyer Andrew Hollman | -6,666 | - | - |
| 2025-10-28 | Meyer Andrew Hollman | -9,999 | - | - |
| 2025-10-28 | Meyer Andrew Hollman | -16,665 | $30.0622 | $500,987 |
| 2025-10-28 | Meyer Andrew Hollman | +6,666 | $10.59 | $70,593 |
| 2025-10-28 | Meyer Andrew Hollman | +9,999 | $4.21 | $42,096 |